Are pro-regenerative therapies the future of osteoarthritis disease modification?

Osteoarthritis Cartilage. 2023 Sep;31(9):1152-1153. doi: 10.1016/j.joca.2023.05.003. Epub 2023 May 15.

Authors

Tonia L Vincent¹, Philip G Conaghan²

Affiliations

¹ Centre for OA Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. Electronic address: Tonia.vincent@kennedy.ox.ac.uk.
² Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, UK. Electronic address: p.conaghan@leeds.ac.uk.

PMID: 37196977
DOI: 10.1016/j.joca.2023.05.003

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Osteoarthritis* / therapy
Regenerative Medicine
Tissue Engineering

Grants and funding